1. FDA approves Thermo Fisher's Oncomine Dx Express Test as companion diagnostic. 2. This expands Thermo Fisher's NGS capabilities in decentralized clinical settings.
FDA approvals typically drive stock values up, similar to prior approvals. For instance, previous diagnostic approvals by TMO have historically spurred positive market responses.
FDA approval enhances TMO's product offering and market position, likely increasing revenue streams. The approval also opens doors for partnerships and further innovations in diagnostics.
Immediate market reactions can be expected due to FDA approval news, affecting sales short-term. Historical trends show significant stock activity following major FDA announcements.